Literature DB >> 19884369

In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.

Lara Liv Bajohr1, Ling Ma, Christian Platte, Oliver Liesenfeld, Lutz F Tietze, Uwe Gross, Wolfgang Bohne.   

Abstract

1-Hydroxy-2-dodecyl-4(1H)quinolone (HDQ) was recently identified as a Toxoplasma gondii inhibitor. We describe here two novel 1-hydroxyquinolones, which displayed 50% inhibitory concentrations 10- and 5-fold lower than that of HDQ. In a mouse model of acute toxoplasmosis, these two compounds and HDQ reduced the percentages of infected peritoneal cells and decreased the parasite loads in lungs and livers. Compound B showed a tendency toward lowering parasite loads in brains in a mouse model of toxoplasmic encephalitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884369      PMCID: PMC2798484          DOI: 10.1128/AAC.01001-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  HDQ (1-hydroxy-2-dodecyl-4(1H)quinolone), a high affinity inhibitor for mitochondrial alternative NADH dehydrogenase: evidence for a ping-pong mechanism.

Authors:  Andrea Eschemann; Alexander Galkin; Walter Oettmeier; Ulrich Brandt; Stefan Kerscher
Journal:  J Biol Chem       Date:  2004-11-08       Impact factor: 5.157

Review 4.  Apicomplexan mitochondrial metabolism: a story of gains, losses and retentions.

Authors:  Frank Seeber; Julien Limenitakis; Dominique Soldati-Favre
Journal:  Trends Parasitol       Date:  2008-09-03

5.  Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases.

Authors:  Ahmad Saleh; Johannes Friesen; Stefan Baumeister; Uwe Gross; Wolfgang Bohne
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

6.  Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

Authors:  I K Srivastava; J M Morrisey; E Darrouzet; F Daldal; A B Vaidya
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

7.  Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

Authors:  Ildiko R Dunay; Markus M Heimesaat; Faris Nadiem Bushrab; Rainer H Müller; Hartmut Stocker; Keikawus Arasteh; Michael Kurowski; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

9.  In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.

Authors:  S Romand; M Pudney; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes.

Authors:  Udo Reischl; Stéphane Bretagne; Dominique Krüger; Pauline Ernault; Jean-Marc Costa
Journal:  BMC Infect Dis       Date:  2003-05-02       Impact factor: 3.090

View more
  10 in total

1.  Acridones Are Highly Potent Inhibitors of Toxoplasma gondii Tachyzoites.

Authors:  P Holland Alday; Erin V McConnell; Jan M Boitz Zarella; Rozalia A Dodean; Papireddy Kancharla; Jane X Kelly; J Stone Doggett
Journal:  ACS Infect Dis       Date:  2021-03-16       Impact factor: 5.084

2.  Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.

Authors:  Fabrice F Boyom; Patrick V T Fokou; Lauve R Y Tchokouaha; Thomas Spangenberg; Alvine N Mfopa; Ruffin M T Kouipou; Cedric J Mbouna; Valerie F Donkeng Donfack; Paul H A Zollo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

3.  Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis.

Authors:  J Stone Doggett; Aaron Nilsen; Isaac Forquer; Keith W Wegmann; Lorraine Jones-Brando; Robert H Yolken; Claudia Bordón; Susan A Charman; Kasiram Katneni; Tracey Schultz; Jeremy N Burrows; David J Hinrichs; Brigitte Meunier; Vern B Carruthers; Michael K Riscoe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

4.  Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase.

Authors:  Katja E Boysen; Kai Matuschewski
Journal:  J Biol Chem       Date:  2011-07-19       Impact factor: 5.157

5.  Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.

Authors:  P Holland Alday; Aaron Nilsen; J Stone Doggett
Journal:  Expert Opin Drug Discov       Date:  2022-08-08       Impact factor: 7.050

6.  A focused small-molecule screen identifies 14 compounds with distinct effects on Toxoplasma gondii.

Authors:  Edwin T Kamau; Ananth R Srinivasan; Mark J Brown; Matthew G Fair; Erin J Caraher; Jon P Boyle
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.

Authors:  Martin McPhillie; Ying Zhou; Kamal El Bissati; Jitender Dubey; Hernan Lorenzi; Michael Capper; Amanda K Lukens; Mark Hickman; Stephen Muench; Shiv Kumar Verma; Christopher R Weber; Kelsey Wheeler; James Gordon; Justin Sanders; Hong Moulton; Kai Wang; Taek-Kyun Kim; Yuqing He; Tatiana Santos; Stuart Woods; Patty Lee; David Donkin; Eric Kim; Laura Fraczek; Joseph Lykins; Farida Esaa; Fatima Alibana-Clouser; Sarah Dovgin; Louis Weiss; Gael Brasseur; Dyann Wirth; Michael Kent; Leroy Hood; Brigitte Meunieur; Craig W Roberts; S Samar Hasnain; Svetlana V Antonyuk; Colin Fishwick; Rima McLeod
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

Review 8.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

Review 9.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

10.  In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization.

Authors:  Céline Christiansen; Deborah Maus; Ellen Hoppenz; Mateo Murillo-León; Tobias Hoffmann; Jana Scholz; Florian Melerowicz; Tobias Steinfeldt; Frank Seeber; Martin Blume
Journal:  Nat Commun       Date:  2022-03-04       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.